Abstract
Background: There are limited data on what is the minimum change that can be detected in cancer patients undergoing treatment with cardiotoxic drugs and are referred for monitoring left ventricular (LV) function.Objective: To assess the variability in the measurement of LV volumes and ejection fraction (EF) in contrast echocardiography and to determine the minimum detectable difference (MDD) between two EF measurements that can be deemed significant.Methods: A total of 150 patients were divided into three groups according to EF (EF <53, 53–60, and >60%). Each group consisted of 50 randomly selected cancer patients who underwent contrast echocardiography between July 2010 and May 2014. Repeated measurements of LV volumes and EF were performed offline by a sonographer and a cardiologist. Inter-observer variability was assessed by analysis of variance. Measurement error was estimated by standard error of measurement and MDD.Results: The 95% confidence interval with a single measurement of EF was 2 percentage points in the groups of patients with EF <53% and EF >60%, and 2.5 percentage points for patients with EF 53–60%. The MDD for EF, end-diastolic volume and end-systolic volume that could be recognized with 95% confidence interval were 4 percentage points, 7 mL and 4 mL, respectively.Conclusion: Contrast echocardiography is a reliable tool for serial measurements of EF to monitor cardiotoxicity due to chemotherapy. In a high-volume echocardiography laboratory with experienced staff, the MDD for EF of 4 percentage points on a good-quality recording demonstrates the high reproducibility of the Simpson’s method using contrast echocardiography.
Highlights
Serial measurements of left ventricular (LV) ejection fraction (EF) are commonly performed in cancer patients to monitor cardiotoxic effects of chemotherapy
5:2 one of the most important questions is ‘Are changes in EF real or due to reader quantification variability?’ contrast 2D echocardiography has been recommended for EF measurements when clinical management depends on accurate assessment of EF such as monitoring cardiotoxicity of chemotherapy [5], there is still interobserver variability of EF among readers [6]
It is difficult for clinicians who monitor changes in EF over time to determine whether differences between the two studies represent a clinically significant change or they are due to measurement error
Summary
Serial measurements of left ventricular (LV) ejection fraction (EF) are commonly performed in cancer patients to monitor cardiotoxic effects of chemotherapy. 5:2 one of the most important questions is ‘Are changes in EF real or due to reader quantification variability?’ contrast 2D echocardiography has been recommended for EF measurements when clinical management depends on accurate assessment of EF such as monitoring cardiotoxicity of chemotherapy [5], there is still interobserver variability of EF among readers [6]. It is difficult for clinicians who monitor changes in EF over time to determine whether differences between the two studies represent a clinically significant change or they are due to measurement error. In a high-volume echocardiography laboratory with experienced staff, the MDD for EF of 4 percentage points on a goodquality recording demonstrates the high reproducibility of the Simpson’s method using contrast echocardiography
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
